{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T07:40:51Z","timestamp":1775634051300,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2005,1,13]],"date-time":"2005-01-13T00:00:00Z","timestamp":1105574400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1007\/s10067-004-1004-6","type":"journal-article","created":{"date-parts":[[2005,1,12]],"date-time":"2005-01-12T08:53:48Z","timestamp":1105520028000},"page":"232-238","source":"Crossref","is-referenced-by-count":24,"title":["Effect of intermittent administration of 200\u00a0IU intranasal salmon calcitonin and low doses of 1\u03b1(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study"],"prefix":"10.1007","volume":"24","author":[{"given":"Evangelia","family":"Kaskani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. P.","family":"Lyritis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Kosmidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Galanos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Andypas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Chorianopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Giagiosis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Iliadou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Karagianis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Katsimichas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Koskinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Matsouka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,1,13]]},"reference":[{"key":"1004_CR1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2265.1989.tb00443.x","volume":"30","author":"K Overgaard","year":"1989","unstructured":"Overgaard K, Riis BJ, Christiansen C, Podenphant J, Johansen JS (1989) Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol 30:435\u2013442","journal-title":"Clin Endocrinol"},{"key":"1004_CR2","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1136\/bmj.305.6853.556","volume":"305","author":"K Overgaard","year":"1992","unstructured":"Overgaard K, Hansen MA, Jensen SB, Christiansen C (1992) Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 305:556\u2013561","journal-title":"BMJ"},{"key":"1004_CR3","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/BF02556148","volume":"48","author":"G Thamsborg","year":"1991","unstructured":"Thamsborg G, Storm TL, Sykulski R, Brineh E, Nielsen HK, Sorensen OH (1991) Effect of different doses of nasal salmon calcitonin on bone mass. Calcif Tissue Int 48:302\u2013307","journal-title":"Calcif Tissue Int"},{"key":"1004_CR4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s002239900076","volume":"59","author":"MC Ellerington","year":"1996","unstructured":"Ellerington MC, Hillard TC, Whitcroft SI, Marsh MS, Lees B, Banks LM, Whitehead MI, Stevenson JC (1996) Intranasal salmon calcitonin for the prevention and treatment of post-menopausal osteoporosis. Calcif Tissue Int 59:6\u201311","journal-title":"Calcif Tissue Int"},{"key":"1004_CR5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0026-0495(84)90187-2","volume":"33","author":"HE Gruber","year":"1984","unstructured":"Gruber HE, Ivey JL, Baylink DJ, Matthews M, Nelp WB, Sisom K, Chesnut CH III (1984) Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 33:295\u2013303","journal-title":"Metabolism"},{"key":"1004_CR6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","volume":"109","author":"CH Chesnut III","year":"2000","unstructured":"Chesnut CH III, Silverman SL, Andriano K, Genari HK, Gimona A, Harris S, Kiel DP, LeBoff MS, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts NB, Baylink DJ (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 109:267\u2013276","journal-title":"Am J Med"},{"key":"1004_CR7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF02556587","volume":"38","author":"G Mazzuoli","year":"1986","unstructured":"Mazzuoli G, Passeri M, Gennari C, Minisola S, Antonelli R, Valtorta C, Palummeri E, Cervellin G, Gonnelli S, Francini G (1986) Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int 38:3\u20138","journal-title":"Calcif Tissue Int"},{"key":"1004_CR8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/0026-0495(85)90120-9","volume":"34","author":"JF Aloia","year":"1985","unstructured":"Aloia JF, Vaswani AN, Kapoor A, Yeh JK, Cohn SH (1985) Treatment of osteoporosis with calcitonin, with and without growth hormone. Metabolism 34:124\u2013129","journal-title":"Metabolism"},{"key":"1004_CR9","first-page":"400","volume-title":"Effect on bone mass and bone turnover of a 2-year intermittent or continuous treatment with salmon calcitonin nasal spray in postmenopausal osteoporotic patients","author":"C Gennari","year":"1992","unstructured":"Gennari C, Agnusdei D, Cepollaro C, Zacchei F, Camporeale A, Montagnani M (1992) Effect on bone mass and bone turnover of a 2-year intermittent or continuous treatment with salmon calcitonin nasal spray in postmenopausal osteoporotic patients. Calcium regulating hormones and bone metabolism. Elsevier, Amsterdam, pp 400\u2013406"},{"key":"1004_CR10","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1002\/art.1780231012","volume":"23","author":"FR Singer","year":"1980","unstructured":"Singer FR, Fredericks RS, Minkin C (1980) Salmon calcitonin therapy for Paget\u2019s disease of bone. Arthritis Rheum 23:1148\u20131154","journal-title":"Arthritis Rheum"},{"key":"1004_CR11","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1172\/JCI107140","volume":"51","author":"JG Haddad","year":"1972","unstructured":"Haddad JG, Caldwell JG Jr (1972) Calcitonin resistance: clinical and immunologic studies in subjects with Paget\u2019s disease of bone treated with porcine and salmon calcitonin. J Clin Invest 51:3133\u20133141","journal-title":"J Clin Invest"},{"key":"1004_CR12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/BF01880446","volume":"1","author":"R Muff","year":"1991","unstructured":"Muff R, Dambacher MA, Fischer JA (1991) Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of postmenopausal osteoporosis. Osteoporos Int 1:72\u201375","journal-title":"Osteoporos Int"},{"key":"1004_CR13","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1210\/jcem-33-5-719","volume":"33","author":"SH Cohn","year":"1971","unstructured":"Cohn SH, Dombrowski CS, Hauser W, Klopper J, Atkins HL (1971) Effects of porcine calcitonin on calcium metabolism in osteoporosis. J Clin Endocrinol Metab 33:719\u2013728","journal-title":"J Clin Endocrinol Metab"},{"key":"1004_CR14","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1210\/jcem-47-3-633","volume":"47","author":"J Jowsey","year":"1978","unstructured":"Jowsey J, Riggs BL, Kelly PJ, Hoffman DL (1978) Calcium and salmon calcitonin in treatment of osteoporosis. J Clin Endocrinol Metab 47:633\u2013639","journal-title":"J Clin Endocrinol Metab"},{"key":"1004_CR15","doi-asserted-by":"crossref","first-page":"5125","DOI":"10.1073\/pnas.84.15.5125","volume":"84","author":"Z Bouizar","year":"1987","unstructured":"Bouizar Z, Roestene WH, Milhaud G (1987) Down-regulation of rat kidney calcitonin receptors by salmon calcitonin infusion evidenced by autoradiography. Proc Natl Acad Sci U S A 84:5125\u20135218","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1004_CR16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1172\/JCI117634","volume":"95","author":"S Takahashi","year":"1995","unstructured":"Takahashi S, Goldring S, Katz M, Hilsenbeck S, Williams R, Roodman GD (1995) Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. J Clin Invest 95:167\u2013171","journal-title":"J Clin Invest"},{"key":"1004_CR17","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1210\/endo.137.3.8603572","volume":"137","author":"S Wada","year":"1996","unstructured":"Wada S, Udagawa N, Nagata N, Martin TJ, Findlay DM (1996) Calcitonin receptor down-regulation relates to calcitonin resistance in mature mouse osteoclasts. Endocrinology 137:1042\u20131048","journal-title":"Endocrinology"},{"key":"1004_CR18","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/8756-3282(95)00280-8","volume":"17","author":"M Rakopoulos","year":"1995","unstructured":"Rakopoulos M, Ikegame M, Findlay DM, Martin TJ, Moseley JM (1995) Short treatment of osteoclasts in bone marrow culture with calcitonin causes prolonged suppression of calcitonin receptor mRNA. Bone 17:447\u2013453","journal-title":"Bone"},{"key":"1004_CR19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000294874","volume":"33","author":"G Perrone","year":"1992","unstructured":"Perrone G, Galoppi P, Valente M, Capri O, D\u2019Ubaldo C, Anelli G, Zichella L (1992) Intranasal salmon calcitonin in postmenopausal osteoporosis: effect of different therapeutic regimens on vertebral and peripheral bone density. Gynecol Obstet Invest 33:168\u2013171","journal-title":"Gynecol Obstet Invest"},{"key":"1004_CR20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/jbmr.5650090110","volume":"9","author":"JY Reginster","year":"1994","unstructured":"Reginster JY, Denis D, Deroisy R, Lecart MP, DeLongueville M, Zegels B, Sarlet N, Noirfalisse P, Franchimont P (1994) Long-term (3\u00a0years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin. J Bone Miner Res 9:69\u201373","journal-title":"J Bone Miner Res"},{"key":"1004_CR21","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF01623389","volume":"6","author":"S Gonnelli","year":"1996","unstructured":"Gonnelli S, Cepollaro C, Pondrelli C, Martini S, Rossi S, Gennari C (1996) Ultrasound parameters in osteoporotic patients treated with salmon calcitonin: a longitudinal study. Osteoporos Int 6:303\u2013307","journal-title":"Osteoporos Int"},{"key":"1004_CR22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/09513599909167526","volume":"13","author":"P Peichl","year":"1999","unstructured":"Peichl P, Rintelen B, Kumpan W, Broll H (1999) Increase of axial and appendicular trabecular and cortical bone density in established osteoporosis with intermittent nasal salmon calcitonin therapy. Gynecol Endocrinol 13:7\u201314","journal-title":"Gynecol Endocrinol"},{"key":"1004_CR23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0378-5122(92)90206-J","volume":"15","author":"P Fioretti","year":"1992","unstructured":"Fioretti P, Gambacciani M, Taponeco F, Melis GB, Capelli N, Spinetti A (1992) Effects of continuous and cyclic nasal calcitonin administration in ovariectomized women. Maturitas 15:225\u2013232","journal-title":"Maturitas"},{"key":"1004_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0002-9343(90)90089-V","volume":"89","author":"K Overgaard","year":"1990","unstructured":"Overgaard K, Hansen MA, Nielsen VA, Riis BJ, Christiansen C (1990) Discontinuous calcitonin treatment of established osteoporosis\u2014effects of withdrawal of treatment. Am J Med 89:1\u20136","journal-title":"Am J Med"},{"key":"1004_CR25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/BF01352011","volume":"53","author":"A Staffan","year":"1993","unstructured":"Staffan A, Eriksson V, Urban Lindgren J (1993) Combined treatment with calcitonin and 1,25-dihydroxyvitamin D3 for osteoporosis in women. Calcif Tissue Int 53:26\u201328","journal-title":"Calcif Tissue Int"},{"key":"1004_CR26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1046\/j.1365-2265.2001.01301.x","volume":"55","author":"M Chen","year":"2002","unstructured":"Chen M, Chow SN (2002) Additive effect of alfacalcidol on bone mineral density of the lumbar spine in Taiwanese postmenopausal women treated with hormone replacement therapy and calcium supplementation: a randomized 2-year study. Clin Endocrinol 55:253\u2013258","journal-title":"Clin Endocrinol"},{"key":"1004_CR27","first-page":"776","volume":"80","author":"R Armamento-Villareal","year":"1995","unstructured":"Armamento-Villareal R, Civitelli R (1995) Estrogen action on bone mass of postmenopausal women is dependent on body mass and initial bone density. J Clin Endocrinol Metab 80:776\u2013782","journal-title":"J Clin Endocrinol Metab"},{"key":"1004_CR28","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 280:2077\u20132082","journal-title":"JAMA"},{"key":"1004_CR29","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1172\/JCI113201","volume":"80","author":"CW Slemenda","year":"1987","unstructured":"Slemenda CW, Hui SL, Longcope C, Johnston CC Jr (1987) Sex steroids and bone mass. A study of changes about the time of menopause. J Clin Invest 80:1261\u20131269","journal-title":"J Clin Invest"},{"key":"1004_CR30","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(87)91671-0","volume":"1","author":"C Christiansen","year":"1987","unstructured":"Christiansen C, Riis BJ, Rodbro P (1987) Prediction of rapid bone loss in postmenopausal women. Lancet 1:1105\u20131108","journal-title":"Lancet"},{"key":"1004_CR31","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1172\/JCI113725","volume":"82","author":"R Civitelli","year":"1988","unstructured":"Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari C (1988) Bone turnover in postmenopausal osteoporosis: effect of calcitonin treatment. J Clin Invest 82:1268\u20131274","journal-title":"J Clin Invest"},{"key":"1004_CR32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/BF00298742","volume":"56","author":"GP Lyritis","year":"1995","unstructured":"Lyritis GP, Magiasis B, Tsakalakos N (1995) Prevention of bone loss in early non surgical and non osteoporotic high bone turnover patients with salmon calcitonin: the role of biochemical bone markers in monitoring high turnover patients under calcitonin treatment. Calcif Tissue Int 56:38\u201341","journal-title":"Calcif Tissue Int"},{"key":"1004_CR33","first-page":"S401","volume":"14","author":"RW Downs","year":"1999","unstructured":"Downs RW, Favus MJ, Walsh BW, Bell NH, Ettinger M, Wang L, Mako B, Smith ME, Gormley GJ, Melton LJ III (1999) Alendronate vs. intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Bone Miner Res 14:S401","journal-title":"J Bone Miner Res"},{"issue":"Suppl 3","key":"1004_CR34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/BF03194338","volume":"7","author":"HF DeLuc","year":"1997","unstructured":"DeLuc HF (1997) 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of osteoporosis. Osteoporos Int 7 [Suppl 3]:24\u201329","journal-title":"Osteoporos Int"},{"key":"1004_CR35","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1210\/jcem.83.11.5270","volume":"83","author":"CJ Haug","year":"1998","unstructured":"Haug CJ, Aukrust P, Haug E, Morkid L, Muller F, Froland SS (1998) Severe deficiency of 1,25-dihydrixyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab 83:3832\u20133838","journal-title":"J Clin Endocrinol Metab"},{"key":"1004_CR36","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1056\/NEJM198904133201506","volume":"320","author":"H Reithel","year":"1989","unstructured":"Reithel H, Koeffler HP, Norman AW (1989) The role of the vitamin D endocrine system in health and disease. N Engl J Med 320:980\u2013991","journal-title":"N Engl J Med"},{"key":"1004_CR37","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1359\/jbmr.2002.17.4.622","volume":"17","author":"T Shibata","year":"2002","unstructured":"Shibata T, Shira-Ishi A, Sato T et al (2002) Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in bone marrow. J Bone Miner Res 17:622\u2013629","journal-title":"J Bone Miner Res"},{"key":"1004_CR38","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1210\/jcem-33-5-752","volume":"33","author":"J Jowsey","year":"1971","unstructured":"Jowsey J, Riggs BL, Goldsmith RS, Kelly PJ, Arnaud CD (1971) Effects of prolonged administration of porcine calcitonin in postmenopausal osteoporosis. J Clin Endocrinol Metab 33:752\u2013758","journal-title":"J Clin Endocrinol Metab"},{"key":"1004_CR39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/BF02555897","volume":"49","author":"S Ljunghall","year":"1991","unstructured":"Ljunghall S, Gardsell P, Johnell O, Larsson K, Lindh E, Obrant K, Sernbo I (1991) Synthetic human calcitonin in postmenopausal osteoporosis: a placebo-controlled, double-blind study. Calcif Tissue Int 49:17\u201319","journal-title":"Calcif Tissue Int"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-004-1004-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-004-1004-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-004-1004-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T08:42:40Z","timestamp":1559119360000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-004-1004-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,13]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["1004"],"URL":"https:\/\/doi.org\/10.1007\/s10067-004-1004-6","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,13]]}}}